by Josh Shea
Novo Nordisk - Google News어제, 15:25
Brokerages expect Novo Nordisk A/S (NYSE:NVO) to announce $0.49 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports.
Two analysts have made estimates for Novo Nordisk A/S’s earnings. The lowest EPS estimate is $0.48 and the highest is $0.50. Novo Nordisk A/S reported earnings per share of $0.38 in the same quarter last year, which suggests a positive year-over-year growth rate of 28.9%. The business is scheduled to announce its next quarterly earnings results on Friday, January 29th.
On average, analysts expect that Novo Nordisk A/S will report full-year earnings of $1.99 per share for the current fiscal year, with EPS estimates ranging from $1.95 to $2.02. For the next year, analysts anticipate that the company will report earnings of $2.29 per share, with EPS estimates ranging from $2.17 to $2.46. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Novo Nordisk A/S.
Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Thursday, October 29th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.02.
Several equities analysts have commented on NVO shares. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Monday, November 9th. Main First Bank AG cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Monday, August 10th. Leerink Swann initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, August 28th. They issued a “market perform” rating and a $56.00 price objective on the stock. Finally, Swedbank upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, September 21st. Two research analysts have rated the stock with a sell rating, five have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $59.00.
Shares of Novo Nordisk A/S (NYSE:NVO) opened at 57.03 on Thursday. Novo Nordisk A/S has a 12 month low of $41.72 and a 12 month high of $60.34. The firm has a market capitalization of $146.33 billion and a P/E ratio of 31.27. The firm’s 50-day moving average price is $54.64 and its 200 day moving average price is $55.97.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins, GLP-1, other protein-related products (NYSE:NVO), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.
Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by MidSouth Newz (http://midsouthnewz.com) and is the sole property of MidSouth Newz. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://midsouthnewz.com/brokerages-anticipate-novo-nordisk-as-nysenvo-to-announce-0-49-eps/46713/
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
설명웹사이트 방문